Enabling access to talicabtagene autoleucel in relapsed/refractory B-cell malignancies; multicenter real-world evidence on delivery, efficacy and safety.
A humanized CAR-T therapy approved in India shows successful implementation across multiple centers, potentially expanding access to this treatment for blood cancers globally.
Talicabtagene autoleucel (tali-cel) is the first humanized CD19-directed CAR-T cell therapy approved in India for relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-N. These findings demonstrate the successful implementation of tali-cel across multiple centers in a large cohort, which might contribute towards improving CAR-T access globally.
What the study was
- Study design
- Cohort study
- Population
- Cancer/disease patients
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Blood cancer journal
Why it surfaced
Matched topic(s): Hematologic malignancies. Study design: Cohort study. Published in high-impact journal. Score 9/10.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.